Researchers disclosed results demonstrating that Wegovy (semaglutide once weekly injection) offers addtional benefits to patients in the SELECT study: Compared to placebo, it cut the chances of dying from Covid-19 by roughly a third.- Novo Nordisk
Researchers have unveiled results demonstrating a benefit that Wegovy has offered to patients in SELECT study: Compared to placebo, it cut the chances of dying from Covid-19 by roughly a third.
Given that obesity is a major risk factor for severe Covid outcomes, it perhaps seems obvious that a medicine that helps people lose weight also helps protect them from the worst tolls of a SARS-CoV-2 infection. But researchers say it might not be as straightforward as that. Some studies have indicated that the drug, also known as semaglutide, bolsters the immune system, tamps down inflammation, and strengthens other organs, including the liver and kidneys, in ways that scientists are only beginning to discover.
“All of that just means somebody is in a better state when they get hit by a medical disaster like a severe Covid infection,” said Benjamin Scirica, a cardiovascular medicine specialist at Brigham and Women’s Hospital in Boston, who presented the data Friday at the European Society of Cardiology’s annual meeting in London. The results were published simultaneously in the Journal of the American College of Cardiology.
See- "The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial"- Benjamin M. Scirica, A. Michael Lincoff, Ildiko Lingvay, Pawel Bogdanski, Silvio Buscemi, Helen Colhoun, Anca-Elena Craciun, Marat Ezhov, Søren Hardt-Lindberg, Ole Kleist Jeppesen, Ana Laura S.A. Matos, Koichi Node, - JACC. Aug 30, 2024. Epublished DOI: 10.1016/j.jacc.2024.08.007.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins